On a surface level I’ve been well aware of the fact that most things in our economy are interconnected. And even more so when it comes to medical research. Academically I’m just in the periphery of things to the point where I know how drug studies are designed and implemented. But for some reason I never really considered how they’re actually funded. But all that changed when I saw a recent news story about an investment banking firm called Laidlaw. The court case is between them and a research firm called Relmada Therapeutics. However, information on the case was a bit hard to come by since part of the news involved a temporary restraining order and associated injunction against Laidlaw. I knew that if I wanted to really get a better idea of how Laidlaw and Company and similar companies worked that I’d need to investigate a bit closer to the source.
It made sense to go directly to Laidlaw’s view of things since they were the ones unable to fully represent themselves due to the court order. What I found really did shed some light on things for me. One of the most notable discoveries for me simply involved the way Laidlaw operated. I assumed that the connection between the two parties would be a fluke. Just one investment among many. But what I discovered is that Laidlaw actually has a very long history of working with medical companies. It drove home the point that Laidlaw and similar organizations are often the main reasons why medical research can occur in the first place.
But what really drove this point home was seeing the faces of some of the people at the top. I’d known the names Matthew Eitner and James Ahern from the case description. But it was very different actually seeing their faces on the site. Even more so, reading about their interests and passions. It became quite clear that they had a pattern of guiding the company to medical research. This really made me consider Laidlaw as a force for overall good. Research needs to be done, and I’d realized just how much it needs to be funded too.